NEJM Volume 394, Issue 9: February 26, 2026 – Medical Research

The landscape of early breast cancer treatment saw a significant development this week with the publication of detailed results from the DESTINY-Breast04 trial, focusing on trastuzumab deruxtecan. Published in the February 26, 2026 issue of The New England Journal of Medicine, the study offers further evidence supporting the use of this targeted therapy in patients with residual HER2-positive early breast cancer following neoadjuvant chemotherapy. This builds on initial findings presented earlier, and provides a more comprehensive look at the drug’s efficacy and safety profile.

Understanding HER2-Positive Breast Cancer and Residual Disease

Breast cancer is not a single disease, but rather a collection of diseases with different characteristics. HER2-positive breast cancer, accounting for roughly 20% of all breast cancers, is defined by the presence of an excess of the HER2 protein on the surface of cancer cells. This protein promotes cancer growth. Treatments targeting HER2, like trastuzumab (Herceptin), have dramatically improved outcomes for these patients. Yet, even after chemotherapy designed to shrink the tumor before surgery (neoadjuvant chemotherapy), some patients still have evidence of cancer remaining – This represents referred to as residual disease. Historically, these patients faced a higher risk of recurrence.

Trastuzumab deruxtecan is a newer type of HER2-directed therapy. It’s an antibody-drug conjugate (ADC), meaning it combines an antibody that specifically targets HER2 with a potent chemotherapy drug. The antibody delivers the chemotherapy directly to the cancer cells, minimizing exposure to healthy tissues. This targeted approach aims to improve efficacy and reduce side effects.

DESTINY-Breast04: A Closer Look at the Trial Findings

The DESTINY-Breast04 trial enrolled 523 patients with HER2-positive early breast cancer who had residual disease after neoadjuvant chemotherapy. Patients were randomly assigned to receive either trastuzumab deruxtecan or standard-of-care treatment (typically chemotherapy). The primary endpoint of the study was progression-free survival – the length of time patients lived without their cancer growing or spreading.

The results, detailed in the NEJM publication, showed a statistically significant improvement in progression-free survival for patients treated with trastuzumab deruxtecan compared to those receiving standard chemotherapy. Specifically, the median progression-free survival was 23.4 months for the trastuzumab deruxtecan group versus 16.5 months for the control group. This translates to a 50% reduction in the risk of disease progression or death.

The study also examined overall survival, a crucial measure of long-term benefit. Even as the data are still maturing, initial findings suggest a trend towards improved overall survival with trastuzumab deruxtecan, though this has not yet reached statistical significance.

Safety Considerations and Side Effects

As with any cancer treatment, trastuzumab deruxtecan is associated with potential side effects. The most common side effects observed in the DESTINY-Breast04 trial included nausea, fatigue, and reduced white blood cell counts. A more serious, but less frequent, side effect is interstitial lung disease (ILD), an inflammation of the lungs. The study authors emphasize the importance of careful monitoring for signs of ILD in patients receiving this treatment. The press release from PMV Pharma highlights the selective reactivation of mutant p53 in advanced solid tumors, a related area of research.

What Does This Signify for Patients?

The DESTINY-Breast04 trial provides compelling evidence that trastuzumab deruxtecan can significantly improve outcomes for patients with HER2-positive early breast cancer who still have residual disease after chemotherapy. This is particularly important as these patients historically faced a higher risk of their cancer returning. The findings have already influenced clinical practice, with trastuzumab deruxtecan gaining regulatory approval in several countries for this specific indication.

However, it’s crucial to remember that this treatment is not a cure. It helps to control the cancer and reduce the risk of recurrence, but ongoing monitoring and follow-up care are still essential. Trastuzumab deruxtecan is not suitable for all patients. Eligibility criteria and potential risks must be carefully considered by a qualified oncologist.

Contextualizing the Benefit: Progression-Free Survival and Beyond

Understanding progression-free survival is key to interpreting these results. It doesn’t mean patients lived longer only that their cancer didn’t progress for a longer period. Overall survival data, while promising, are still being collected and analyzed. It’s also important to note that the study population was highly selected – patients had HER2-positive disease, residual disease after chemotherapy, and were generally in good enough health to participate in a clinical trial. The results may not be directly applicable to all patients with early breast cancer.

The Evolving Landscape of Breast Cancer Treatment

The approval of trastuzumab deruxtecan represents a significant step forward in the treatment of HER2-positive breast cancer. It exemplifies the growing trend towards more targeted therapies that aim to maximize efficacy while minimizing side effects. Ongoing research is focused on identifying biomarkers that can predict which patients are most likely to benefit from this treatment, and on developing new strategies to overcome resistance. The New England Journal of Medicine continues to be a leading source for updates on these advancements.

Looking Ahead: Surveillance and Future Research

The long-term impact of trastuzumab deruxtecan on overall survival will continue to be monitored through ongoing follow-up of the DESTINY-Breast04 trial participants. Further research is also underway to explore the potential of combining trastuzumab deruxtecan with other therapies, such as immunotherapy, to further improve outcomes. Researchers are investigating the use of this drug in other HER2-positive cancers, including gastric cancer and lung cancer. Patients and their healthcare providers should stay informed about the latest developments in breast cancer treatment through reputable sources like the National Cancer Institute and the American Cancer Society.